Atlas Trials

The Effect o f Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Betrixiban, an Oral FXa Antagonist

Clinical trial NCT03397888 · COMPLETED

Trial details

NCT number
NCT03397888
Sponsor
Portola Pharmaceuticals
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Hepatic Impairment
Start date
2017-11-16
Primary completion
2018-01-16
Enrollment
32

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.